In a report released today, Jason McCarthy from Maxim Group maintained a Buy rating on Inovio Pharmaceuticals (NASDAQ: INO), with a price target of $8. The company’s shares closed on Friday at $5.26.
McCarthy commented:
“Inovio and partner GeneOne Life Science (KSE: 011000 – NR) have dosed the first patient in a P1 study of DNA-based vaccine GLS-6150 in hepatitis C..”
According to TipRanks.com, McCarthy is a 5-star analyst with an average return of 19.0% and a 52.9% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Sonoma Pharmaceuticals Inc.
Inovio Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $11.
See today’s analyst top recommended stocks >>
The company has a one-year high of $7 and a one-year low of $3.64. Currently, Inovio Pharmaceuticals has an average volume of 810.9K.
Based on the recent corporate insider activity of 21 insiders, corporate insider sentiment is negative on the stock. Most recently, in July 2018, Peter Kies, the CFO of INO sold 35,000 shares for a total of $155,250.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Inovio Pharmaceuticals, Inc. engages in the development of active DNA immunotherapies for cancer and infectious diseases. Its portfolio of immune therapies includes SynCon immunotherapies and electroporation delivery systems. The company was founded on June 29, 1983 and is headquartered in Plymouth Meeting, PA.
